Use of Oral Fluoroquinolones in Canada: A Drug Utilization Study Update

Use of Oral Fluoroquinolones in Canada: A Drug Utilization Study Update

Use of Oral Fluoroquinolones in Canada: A Drug Utilization Study Update

HC0073

Overview

Background
  • In January 2017, Health Canada issued a risk communication to restrict the use of fluoroquinolone antibiotics due to their potentially persistent and disabling side effects. Updates to the product labels were also made.
  • It is unknown if fluoroquinolone utilization patterns have changed since these regulatory actions were implemented.
  • At the request of Health Canada, our previous drug utilization study will be updated to determine if further regulatory actions are needed.
Objectives
  • The main objectives of this study are to update our previous study to describe fluoroquinolone utilization trends from 2008 to 2022 and to assess the impact of the risk minimization measures introduced in 2017.

Manuscripts

Presentations

Project Team

Site Investigator
Donica Janzen PhD
Saskatchewan
Site Investigator
Nick Daneman MD, FRCPC, MSc
Ontario
Site Investigator
Daniel Dutton PhD
Atlantic
Site Investigator
Lisa Lix BSHEc, MSc, PhD, P Stat
Manitoba
Site Investigator
Greg Carney BSc, PhD
British Columbia
Site Investigator
Paul Ronksley PhD
Alberta
Analyst
Xue Feng
Saskatchewan
Analyst
Xinya Lu PhD
Saskatchewan
Analyst
Vicki Ling
Ontario
Analyst
Devin Manning
Atlantic
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Tarita Miller BSc
British Columbia